278 related articles for article (PubMed ID: 36613980)
1. Microbiome and Metabolomics in Liver Cancer: Scientific Technology.
Ganesan R; Yoon SJ; Suk KT
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613980
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics in cancer research and emerging applications in clinical oncology.
Schmidt DR; Patel R; Kirsch DG; Lewis CA; Vander Heiden MG; Locasale JW
CA Cancer J Clin; 2021 Jul; 71(4):333-358. PubMed ID: 33982817
[TBL] [Abstract][Full Text] [Related]
3. Clinical and metabolomics analysis of hepatocellular carcinoma patients with diabetes mellitus.
Xia H; Chen J; Sekar K; Shi M; Xie T; Hui KM
Metabolomics; 2019 Nov; 15(12):156. PubMed ID: 31773292
[TBL] [Abstract][Full Text] [Related]
4. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery.
Shao Y; Zhu B; Zheng R; Zhao X; Yin P; Lu X; Jiao B; Xu G; Yao Z
J Proteome Res; 2015 Feb; 14(2):906-16. PubMed ID: 25483141
[TBL] [Abstract][Full Text] [Related]
5. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
[TBL] [Abstract][Full Text] [Related]
6. Multi-omic approaches for characterization of hepatocellular carcinoma.
Ressom HW; Di Poto C; Ferrarini A; Yunli Hu ; Nezami Ranjbar MR; Ehwang Song ; Varghese RS; Minkun Wang ; Shiyue Zhou ; Rui Zhu ; Yiming Zuo ; Tadesse MG; Mechref Y
Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():3437-3440. PubMed ID: 28269041
[TBL] [Abstract][Full Text] [Related]
7. The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and (13) C-isotope based metabolomics.
Darpolor MM; Basu SS; Worth A; Nelson DS; Clarke-Katzenberg RH; Glickson JD; Kaplan DE; Blair IA
NMR Biomed; 2014 Apr; 27(4):381-9. PubMed ID: 24497316
[TBL] [Abstract][Full Text] [Related]
8. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
[TBL] [Abstract][Full Text] [Related]
9. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics.
Huang Q; Tan Y; Yin P; Ye G; Gao P; Lu X; Wang H; Xu G
Cancer Res; 2013 Aug; 73(16):4992-5002. PubMed ID: 23824744
[TBL] [Abstract][Full Text] [Related]
10. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
[TBL] [Abstract][Full Text] [Related]
11. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma.
Wang X; Zhang A; Sun H
Hepatology; 2013 May; 57(5):2072-7. PubMed ID: 23150189
[TBL] [Abstract][Full Text] [Related]
12. Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma.
Nie W; Yan L; Lee YH; Guha C; Kurland IJ; Lu H
Mass Spectrom Rev; 2016; 35(3):331-49. PubMed ID: 24890331
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.
De Matteis S; Ragusa A; Marisi G; De Domenico S; Casadei Gardini A; Bonafè M; Giudetti AM
Oxid Med Cell Longev; 2018; 2018():7512159. PubMed ID: 30524660
[TBL] [Abstract][Full Text] [Related]
14. [Cancer metabolism: a novel perspective on precision diagnosis and treatment for liver cancer].
Ning Z; Tan G
Zhonghua Wai Ke Za Zhi; 2020 Jan; 58(1):31-36. PubMed ID: 31902167
[TBL] [Abstract][Full Text] [Related]
15. Dynamic metabolic change is indicative of inflammation-induced transformation of hepatic cells.
Peng B; Liu F; Han R; Luo G; Cathopoulis T; Lu K; Li X; Yang L; Liu GY; Cai JC; Shi SL
Int J Biochem Cell Biol; 2015 Sep; 66():45-58. PubMed ID: 26205150
[TBL] [Abstract][Full Text] [Related]
16. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
[TBL] [Abstract][Full Text] [Related]
17. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma.
Han J; Han ML; Xing H; Li ZL; Yuan DY; Wu H; Zhang H; Wang MD; Li C; Liang L; Song YY; Xu AJ; Wu MC; Shen F; Xie Y; Yang T
Int J Cancer; 2020 Mar; 146(6):1741-1753. PubMed ID: 31361910
[TBL] [Abstract][Full Text] [Related]
18. NFκB activation demarcates a subset of hepatocellular carcinoma patients for targeted therapy.
Ramesh V; Selvarasu K; Pandian J; Myilsamy S; Shanmugasundaram C; Ganesan K
Cell Oncol (Dordr); 2016 Dec; 39(6):523-536. PubMed ID: 27562587
[TBL] [Abstract][Full Text] [Related]
19. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.
Beyoğlu D; Imbeaud S; Maurhofer O; Bioulac-Sage P; Zucman-Rossi J; Dufour JF; Idle JR
Hepatology; 2013 Jul; 58(1):229-38. PubMed ID: 23463346
[TBL] [Abstract][Full Text] [Related]
20. Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
Han J; Qin WX; Li ZL; Xu AJ; Xing H; Wu H; Zhang H; Wang MD; Li C; Liang L; Quan B; Yan WT; Shen F; Wu MC; Yang T
Clin Chim Acta; 2019 Jan; 488():68-75. PubMed ID: 30389456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
